`TOTAL PRESCRIPTIONS
`U.S. UNITS BY PRODUCT, INCLUDING GENERICS
`Q4 2012 – Q3 2014
`
`2012
`
`Q4
`
`Q1
`
`Q2
`
`Q3
`
`Q4
`
`Q1
`
`2013
`
`2014
`
`Q2
`
`Q3
`
`Total
`
`Ixempra®
`Kadcyla®²
`Perjeta®
`Tykerb®
`Xeloda®
`
`Total
`
`Ixempra®
`Kadcyla®
`Perjeta®
`Tykerb®
`Xeloda®
`
`Total
`
`
`
`
`
`
`
`
`
`55
`0
`140
`6,059
`72,329
`
`78,583
`
`0.1%
`
`0.2%
`7.7%
`92.0%
`
`
`
`
`
`56
`14
`180
`5,336
`66,830
`
`72,416
`
`0.1%
`0.0%
`0.2%
`7.4%
`92.3%
`
`
`
`
`
`60
`145
`214
`4,494
`67,966
`
`72,879
`
`0.1%
`0.2%
`0.3%
`6.2%
`93.3%
`
`
`
`
`
`28
`257
`187
`4,000
`68,381
`
`72,853
`
`0.0%
`0.4%
`0.3%
`5.5%
`93.9%
`
`
`
`
`
`53
`314
`217
`3,831
`68,170
`
`72,585
`
`0.1%
`0.4%
`0.3%
`5.3%
`93.9%
`
`
`
`
`
`25
`299
`315
`3,552
`66,377
`
`70,568
`
`0.0%
`0.4%
`0.4%
`5.0%
`94.1%
`
`
`
`
`
`3
`275
`333
`3,646
`73,454
`
`77,711
`
`0.0%
`0.4%
`0.4%
`4.7%
`94.5%
`
`
`
`
`
`11
`203
`287
`3,482
`73,111
`
`77,094
`
`0.0%
`0.3%
`0.4%
`4.5%
`94.8%
`
`
`
`
`
`291
`1,507
`1,873
`34,400
`556,618
`
`594,689
`
`0.0%
`0.3%
`0.3%
`5.8%
`93.6%
`
`100.0%
`
`100.0%
`
`100.0%
`
`100.0%
`
`100.0%
`
`100.0%
`
`100.0%
`
`100.0%
`
`100.0%
`
`Notes & Sources:
`¹ Excludes Herceptin®.
`² Annual Kadcyla® prescriptions totaled 730 in 2013.
`Kadcyla® is indicated as a single agent for the treatment of people with HER2-positive metastatic breast cancer who have received prior treatment with Herceptin® and a taxane
`chemotherapy. See, e.g., Exhibit 2317. In contrast:
`Xeloda® can be used to treat colon, rectal, and other cancers. See, e.g., Exhibit 2246.
`Perjeta® received FDA approval for neoadjuvant breast cancer therapy. See, e.g., Exhibit 2211.
`Tykerb® is used to treat breast cancer, but is prescribed with a second medicine (Xeloda® or Femara®). See, e.g., Exhibit 2342.
`(These assertions and sources can be found in the report.)
`Includes brand and generic values.
`Ixempra® includes brand IXEMPRA 10/2007 BM0, identified in field 'Product.'
`Kadcyla® includes brand KADCYLA 02/2013 GTC, identified in field 'Product.'
`Perjeta® includes brand PERJETA 06/2012 GTC, identified in field 'Product.'
`Tykerb® includes brand TYKERB 03/2007 GSK, identified in field 'Product.'
`Xeloda® includes brand XELODA 05/1998 GTC, identified in field 'Product,' and generic capecitabine, identified in field 'Combined Molecule.'
`Includes Xeloda® (capecitabine), which is indicated for use with Tykerb® (lapatinib) in second-line therapy. Excludes other chemotherapeutic agents that may be used to treat breast
`cancer (e.g., vinorelbine), which are indicated for the use of other cancers. See Exhibit 2218 and Exhibit 2343.
`Values reflect field 'TRx'.
`Percentage calculated as percent of quarterly total.
`Products identified from Exhibit 2103 and Exhibit 2224.
`Data from IMS Health.
`
`IMMUNOGEN 2243, pg. 1
`Phigenix v. Immunogen
`IPR2014-00676
`
`